“证治代谢组学”假说的研究思路与实践  

Research and Practice of the Hypothesis of "Treatment by Syndrome and Metabonomics"

作　　者：王恒和[1] 张富赓[2] 程刚[3] 刘兴磊[3] 侯雅竹[1] 牛子长[1] 张妍[1] 王强[1] 姚蓥 孙伯驹 

机构地区：[1]天津中医药大学第一附属医院心血管科,天津市300193 [2]天津市环湖医院药剂科 [3]天津中医药大学研究生院

出　　处：《中国全科医学》2016年第19期2344-2347,共4页Chinese General Practice

基　　金：国家自然科学基金面上项目(81573849)

摘　　要："证候"基础研究是中医药学现代研究的关键问题之一,是证型规范化和客观化的前提,而代谢组学的方法和技术给"证候"基础研究带来了曙光。通过多年中西医结合临床实践发现,病理状态下不同中医证型间及辨证论治前后患者存在体内代谢物差异,因此在充分回顾、分析既往文献的基础上提出"证治代谢组学"的研究设想。"证治代谢组学"假说以冠心病(CHD)为研究载体,以"证"为切入点,主要探讨基于代谢组学的CHD生化代谢谱与其中医证型的相关性。本文主要介绍了"证治代谢组学"假说的概念与内涵、研究背景、研究依据、研究实践、特色及临床意义。The basic research of TCM syndromes is one of the key problems in the modern research of TCM, and is the premise for the standardization and objectivity for TCM syndrome types. The method and technology of metabonomics provide a new boost for the basic research of TCM syndromes. By multiple years of clinical practice of TCM combined with WM, it has been found that there are differences in metabolites in patients among different TCM syndrome types and between before and after syndrome differentiation. Therefore, based on the adequate review and analysis of the previous literature, the hypothesis of ＂ treatment by syndrome and metabonomics＂ was suggested. With coronary heart disease （CHD） as the research carrier and syndrome as the entry point, the hypothesis of ＂ treatment by syndromes and metabonomics＂ is to investigate the correlation between CHD biochemical metabolism spectrum based on metabonomies and TCM syndrome types. The paper introduces the concept and connotation, the background, basis and practice of research, features and clinical value of the hypothesis of ＂ treatment by syndrome and metabonomics＂ .

关 键 词：证候 代谢组学 证治代谢组学 冠心病 

分 类 号：R541.4[医药卫生—心血管疾病]